Investors Seek Justice: Class Action Against Soleno Therapeutics Over Securities Violations

Class Action Lawsuit Against Soleno Therapeutics

Investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) have become the focus of a significant legal battle as the DJS Law Group initiates a class action lawsuit against the company. This legal action centers around allegations of securities law violations that reportedly misled shareholders regarding the company’s performance and potential.

Background of the Case

The lawsuit targets particular transactions and communications made by Soleno between March 26, 2025, and November 4, 2025. During this timeframe, the company is accused of disseminating false and misleading information to investors, which may have influenced their decisions to purchase or hold shares. Such claims are particularly critical as they relate to the company's Phase 3 clinical trials of its drug candidate, diazoxide choline extended-release tablets, branded as DCCR.

A primary concern raised in the lawsuit is that Soleno downplayed safety issues related to DCCR, thereby creating a facade of commercial viability that did not reflect the underlying realities. The complaint alleges that the company’s statements during the class period were materially misleading, which potentially contributed to significant financial losses for investors who acted on this information.

Legal Representation by DJS Law Group

DJS Law Group, known for advocating on behalf of investors, emphasizes the importance of securing justice for those affected. The firm, which specializes in securities class actions, corporate governance disputes, and mergers and acquisitions advisory, invites affected shareholders to consider becoming lead plaintiffs in the case. Participating as a lead plaintiff is not a requirement for recovery, allowing more investors to regain their losses.Should enough evidence be collected to support the accusations, resolved cases often lead to settlements or other forms of reparations that mitigate investors' financial suffering.

Why This Matters

The implications of this lawsuit stretch beyond just Soleno's financial future; they potentially illuminate broader issues within the pharmaceutical industry concerning transparency and accountability to investors. By calling attention to alleged misconduct, the lawsuit seeks to uphold the principles of fair trading and ethical obligations of public companies to their shareholders. Investor trust is paramount, and any erosion of this trust can have long-reaching effects not just on individual stocks, but on market confidence as a whole.

Next Steps for Shareholders

Shareholders who acquired shares within the specified class period are encouraged to reach out to DJS Law Group to discuss their eligibility for participation in the class action lawsuit. With a deadline set for May 5, 2026, it is crucial for impacted investors to take prompt action to ensure their voices are heard and losses addressed.

Conclusion

As this situation unfolds, the focus remains on the judicial process and the outcome of the case against Soleno Therapeutics. For investors, being informed and asserting one’s rights could not only provide remedies for past losses but also build a stronger foundation for investor protections in the future. The DJS Law Group aims to fight for the rights of affected investors and restore their faith in financial markets.

For those who wish to learn more about the class action or need legal assistance, the DJS Law Group remains at the forefront, ready to provide counsel tailored to the unique circumstances of each investor.

If you believe you are affected by these developments or require any legal help, please contact:

David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]